Tejshri Shah1, Jane Greig2, Linda Margaretha van der Plas3, Jay Achar2, Grazia Caleo2, James Sylvester Squire4, Alhaji Sayui Turay5, Grace Joshy6, Catherine D'Este6, Emily Banks6, Florian Vogt7, Kamalini Lokuge8. 1. Manson Unit, Médecins Sans Frontières, London, UK; Department of Paediatrics, St Mary's Hospital, Imperial College NHS Healthcare Trust, London, UK. Electronic address: tejshrishah@gmail.com. 2. Manson Unit, Médecins Sans Frontières, London, UK. 3. Department of Medical Oncology, Antoni van Leeuwenhoek Hospital, Netherlands Cancer Institute, Amsterdam, Netherlands. 4. Ministry of Health and Sanitation of Sierra Leone, Kailahun, Sierra Leone. 5. Ministry of Health and Sanitation of Sierra Leone, Bo, Sierra Leone. 6. National Centre for Epidemiology and Population Health, Research School of Population Health, Australian National University, Canberra, Australia. 7. Médecins Sans Frontières, Brussels, Belgium. 8. Manson Unit, Médecins Sans Frontières, London, UK; National Centre for Epidemiology and Population Health, Research School of Population Health, Australian National University, Canberra, Australia.
Abstract
BACKGROUND: Médecins Sans Frontières (MSF) opened Ebola management centres (EMCs) in Sierra Leone in Kailahun in June, 2014, and Bo in September, 2014. Case fatality in the west African Ebola virus disease epidemic has been highest in children younger than 5 years. Clinical data on outcomes can provide important evidence to guide future management. However, such data on children are scarce and disaggregated clinical data across all ages in this epidemic have focussed on symptoms reported on arrival at treatment facilities, rather than symptoms and signs observed during admission. We aimed to describe the clinical characteristics of children aged 5 years and younger admitted to the MSF EMCs in Bo and Kailahun, and any associations between these characteristics and mortality. METHODS: In a retrospective cohort study, we included data from children aged 5 years and younger with laboratory-confirmed Ebola virus disease admitted to EMCs between June and December, 2014. We described epidemiological, demographic, and clinical characteristics and viral load (measured using Ebola virus cycle thresholds [Ct]), and assessed their association with death using Cox regression modelling. FINDINGS: We included 91 children in analysis; 52 died (57·1%). Case fatality was higher in children aged less than 2 years (76·5% [26/34]) than those aged 2-5 years (45·6% [26/57]; adjusted HR 3·5 [95% CI 1·5-8·5]) and in those with high (Ct<25) versus low (Ct≥25) viral load (81·8% [18/22] vs 45·9% [28/61], respectively; adjusted HR 9·2 [95% CI 3·8-22·5]). Symptoms observed during admission included: weakness 74·7% (68); fever 70·8% (63/89); distress 63·7% (58); loss of appetite 60·4% (55); diarrhoea 59·3% (54); and cough 52·7% (48). At admission, 25% (19/76) of children were afebrile. Signs significantly associated with death were fever, vomiting, and diarrhoea. Hiccups, bleeding, and confusion were observed only in children who died. INTERPRETATION: This description of the clinical features of Ebola virus disease over the duration of illness in children aged 5 years and younger shows symptoms associated with death and a high prevalence of distress, with implications for clinical management. Collection and analysis of age-specific data on Ebola is very important to ensure that the specific vulnerabilities of children are addressed. FUNDING: No specific funding was received for this study. EB is supported by the National Health and Medical Research Council of Australia.
BACKGROUND: Médecins Sans Frontières (MSF) opened Ebola management centres (EMCs) in Sierra Leone in Kailahun in June, 2014, and Bo in September, 2014. Case fatality in the west African Ebola virus disease epidemic has been highest in children younger than 5 years. Clinical data on outcomes can provide important evidence to guide future management. However, such data on children are scarce and disaggregated clinical data across all ages in this epidemic have focussed on symptoms reported on arrival at treatment facilities, rather than symptoms and signs observed during admission. We aimed to describe the clinical characteristics of children aged 5 years and younger admitted to the MSF EMCs in Bo and Kailahun, and any associations between these characteristics and mortality. METHODS: In a retrospective cohort study, we included data from children aged 5 years and younger with laboratory-confirmed Ebola virus disease admitted to EMCs between June and December, 2014. We described epidemiological, demographic, and clinical characteristics and viral load (measured using Ebola virus cycle thresholds [Ct]), and assessed their association with death using Cox regression modelling. FINDINGS: We included 91 children in analysis; 52 died (57·1%). Case fatality was higher in children aged less than 2 years (76·5% [26/34]) than those aged 2-5 years (45·6% [26/57]; adjusted HR 3·5 [95% CI 1·5-8·5]) and in those with high (Ct<25) versus low (Ct≥25) viral load (81·8% [18/22] vs 45·9% [28/61], respectively; adjusted HR 9·2 [95% CI 3·8-22·5]). Symptoms observed during admission included: weakness 74·7% (68); fever 70·8% (63/89); distress 63·7% (58); loss of appetite 60·4% (55); diarrhoea 59·3% (54); and cough 52·7% (48). At admission, 25% (19/76) of children were afebrile. Signs significantly associated with death were fever, vomiting, and diarrhoea. Hiccups, bleeding, and confusion were observed only in children who died. INTERPRETATION: This description of the clinical features of Ebola virus disease over the duration of illness in children aged 5 years and younger shows symptoms associated with death and a high prevalence of distress, with implications for clinical management. Collection and analysis of age-specific data on Ebola is very important to ensure that the specific vulnerabilities of children are addressed. FUNDING: No specific funding was received for this study. EB is supported by the National Health and Medical Research Council of Australia.
Authors: Xuan Liu; Emily Speranza; César Muñoz-Fontela; Sam Haldenby; Natasha Y Rickett; Isabel Garcia-Dorival; Yongxiang Fang; Yper Hall; Elsa-Gayle Zekeng; Anja Lüdtke; Dong Xia; Romy Kerber; Ralf Krumkamp; Sophie Duraffour; Daouda Sissoko; John Kenny; Nichola Rockliffe; E Diane Williamson; Thomas R Laws; Magassouba N'Faly; David A Matthews; Stephan Günther; Andrew R Cossins; Armand Sprecher; John H Connor; Miles W Carroll; Julian A Hiscox Journal: Genome Biol Date: 2017-01-19 Impact factor: 13.583
Authors: Michael A Smit; Ian C Michelow; Justin Glavis-Bloom; Vanessa Wolfman; Adam C Levine Journal: Clin Infect Dis Date: 2016-10-25 Impact factor: 9.079
Authors: Felicity Fitzgerald; Kevin Wing; Asad Naveed; Musa Gbessay; J C G Ross; Francesco Checchi; Daniel Youkee; Mohamed Boie Jalloh; David E Baion; Ayeshatu Mustapha; Hawanatu Jah; Sandra Lako; Shefali Oza; Sabah Boufkhed; Reynold Feury; Julia Bielicki; Elizabeth Williamson; Diana M Gibb; Nigel Klein; Foday Sahr; Shunmay Yeung Journal: Emerg Infect Dis Date: 2018-02 Impact factor: 6.883
Authors: Alicia E Genisca; Kelsey Butler; Monique Gainey; Tzu-Chun Chu; Lawrence Huang; Eta N Mbong; Stephen B Kennedy; Razia Laghari; Fiston Nganga; Rigobert F Muhayangabo; Himanshu Vaishnav; Shiromi M Perera; Moyinoluwa Adeniji; Adam C Levine; Ian C Michelow; Andrés Colubri Journal: PLoS Negl Trop Dis Date: 2022-10-12
Authors: Shevin T Jacob; Ian Crozier; William A Fischer; Angela Hewlett; Colleen S Kraft; Marc-Antoine de La Vega; Moses J Soka; Victoria Wahl; Anthony Griffiths; Laura Bollinger; Jens H Kuhn Journal: Nat Rev Dis Primers Date: 2020-02-20 Impact factor: 52.329
Authors: Grazia Caleo; Foivi Theocharaki; Kamalini Lokuge; Helen A Weiss; Leena Inamdar; Francesco Grandesso; Kostas Danis; Biagio Pedalino; Gary Kobinger; Armand Sprecher; Jane Greig; Gian Luca Di Tanna Journal: Lancet Infect Dis Date: 2020-06-25 Impact factor: 71.421